Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405538 | 1.00 | ALDH1A1 (0.58) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL14925267 | 0.86 | ALDH1A1 (0.58) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL14925266 | 0.78 | CLK1 (0.56) | ALDH1A1RAB9AMAPTKDM4ELMNA | |
| SCHEMBL2554440 | 0.78 | APP (0.54) | NPC1RAB9AMAPTKDM4ELMNA | |
| SCHEMBL14916183 | 0.77 | ERN1 (0.61) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL4929202 | 0.70 | KDM4E (0.65) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL3468735 | 0.69 | AR (0.70) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| Acetic Acid SCHEMBL2099175 | 0.68 | APP (0.53) | MAPTSULT1A1APP | |
| SCHEMBL2549277 | 0.68 | SULT1A1 (0.53) | ALDH1A1NPC1RAB9AMAPTKDM4E | |
| SCHEMBL30406206 | 0.68 | SULT1A1 (0.53) | ALDH1A1NPC1RAB9AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| CN-103079558-A | IRE-1 alpha inhibitors | MANNKIND CORP | 2013-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ALDH1A1 2024/4885NPC1 822/4885RAB9A 1146/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ALDH1A1 1815/4885NPC1 628/4885RAB9A 1149/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | ALDH1A1 2024/4885NPC1 822/4885RAB9A 1146/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | ALDH1A1 1815/4885NPC1 628/4885RAB9A 1149/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | ALDH1A1 2036/4885NPC1 705/4885RAB9A 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.